ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/20/23 | $46,000,000 | Series B-1 |
Ascenta Capital Lilly Asia Ventures OrbiMed Advisors Sirona Capital SR One | undisclosed |
